Voriconazole in the treatment of invasive mold infections in transplant recipients

被引:54
|
作者
Fortún, J [1 ]
Martín-Dávila, P [1 ]
Sánchez, MA [1 ]
Pintado, V [1 ]
Alvarez, ME [1 ]
Sánchez-Sousa, A [1 ]
Moreno, S [1 ]
机构
[1] Hosp Ramon y Cajal, Serv Enfermedades Infecciosas, E-28034 Madrid, Spain
关键词
D O I
10.1007/s10096-003-0960-0
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Mortality due to invasive mold infections in solid organ transplant recipients is very high despite therapy with amphotericin B, including lipid formulations. Voriconazole is a triazole with a good activity against molds, including Aspergillus spp. and Scedosporium spp. Experience with voriconazole is limited, but preliminary results in patients with these infections are promising. Reported here is the experience with voriconazole administered on a compassionate-use basis to five patients with invasive mold infections: four solid organ recipients and one patient with an autoimmune disorder. Four patients had invasive Aspergillus fumigatus infection (3 lung infections, 1 abdominal infection) and one had invasive ocular Scedosporium apiospermum infection. The MIC of voriconazole was less than or equal to1 mug/ml for all isolates (NCCLS performance standards for microdilution assay, proposed standard M38-P). Voriconazole was administered as primary therapy in a patient with Scedosporium infection and, in patients with Aspergillus infections, after persistence of positive culture despite a cumulative dose of 3 g of a lipid formulation of amphotericin B. Voriconazole was administered for a median time of 80 days (range, 60-90 days). No visual disturbances were observed, but one patient presented a moderate increase in liver enzymes. An increase in the levels of immunosuppressive drugs (tacrolimus or cyclosporine) was detected in all patients during coadministration with voriconazole. A clinical response was observed in all patients (complete response, n=3; partial response, n=2), and a microbiological response was observed in all but one patient. Furthermore, a good relationship between the MIC of voriconazole and outcome was observed. Voriconazole is an effective and safe therapy for treatment of invasive mold infections in solid organ recipients. To avoid toxicity with this drug, however, the dosing of immunosuppressive drugs must be reduced.
引用
收藏
页码:408 / 413
页数:6
相关论文
共 50 条
  • [31] Invasive Non-Aspergillus Mold Infections in Transplant Recipients, United States, 2001-2006
    Park, Benjamin J.
    Pappas, Peter G.
    Wannemuehler, Kathleen A.
    Alexander, Barbara D.
    Anaissie, Elias J.
    Andes, David R.
    Baddley, John W.
    Brown, Janice M.
    Brumble, Lisa M.
    Freifeld, Alison G.
    Hadley, Susan
    Herwaldt, Loreen
    Ito, James I.
    Kauffman, Carol A.
    Lyon, G. Marshall
    Marr, Kieren A.
    Morrison, Vicki A.
    Papanicolaou, Genovefa
    Patterson, Thomas F.
    Perl, Trish M.
    Schuster, Mindy G.
    Walker, Randall
    Wingard, John R.
    Walsh, Thomas J.
    Kontoyiannis, Dimitrios P.
    EMERGING INFECTIOUS DISEASES, 2011, 17 (10) : 1855 - 1864
  • [32] Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole
    Imhof, A
    Balajee, SA
    Fredricks, DN
    Englund, JA
    Marr, KA
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) : 743 - 746
  • [33] Genomic characterization of recurrent mold infections in thoracic transplant recipients
    Messina, Julia A.
    Wolfe, Cameron R.
    Hemmersbach-Miller, Marion
    Milano, Carmelo
    Todd, Jamie L.
    Reynolds, John
    Alexander, Barbara D.
    Schell, Wiley A.
    Cuomo, Christina A.
    Perfect, John R.
    TRANSPLANT INFECTIOUS DISEASE, 2018, 20 (05)
  • [34] Ochroconis gallopava: a dematiaceous mold causing infections in transplant recipients
    Qureshi, Zubair A.
    Kwak, Eun J.
    Nguyen, M. Hong
    Silveira, Fernanda P.
    CLINICAL TRANSPLANTATION, 2012, 26 (01) : E17 - E23
  • [35] Mold infections in solid organ transplant recipients in indian setting
    Enaganthi, Niveditha
    Sridhar, Kripa
    Rajkumar, J.
    Swaminathan S, Subramaniam
    Verghese, Joy
    Selva, Sreenivas Reddy
    Muthukumar
    Balaji
    Lokeshwari
    Mouleeswaran
    MEDICAL MYCOLOGY, 2022, 60 (SUPP 1) : 215 - +
  • [36] Novel agents in the treatment of invasive fungal infections in solid organ transplant recipients
    Cabrera, Nicolo L.
    George, Ige A.
    Rauseo, Adriana M.
    Mazi, Patrick
    Spec, Andrej
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2022, 27 (04) : 235 - 242
  • [37] Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis
    Husain, Shahid
    Silveira, Fernanda P.
    Azie, Nkechi
    Franks, Billy
    Horn, David
    MEDICAL MYCOLOGY, 2017, 55 (03) : 269 - 277
  • [38] Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?
    Roth, Romain Samuel
    Masouridi-Levrat, Stavroula
    Chalandon, Yves
    Mamez, Anne-Claire
    Giannotti, Federica
    Riat, Arnaud
    Fischer, Adrien
    Poncet, Antoine
    Glampedakis, Emmanouil
    Van Delden, Christian
    Kaiser, Laurent
    Neofytos, Dionysios
    OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (01):
  • [39] Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis
    Siwek, GT
    Dodgson, KJ
    de Magalhaes-Silverman, M
    Bartelt, LA
    Kilborn, SB
    Hoth, PL
    Diekema, DJ
    Pfaller, MA
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) : 584 - 587
  • [40] Invasive pneumococcal infections in adult lung transplant recipients
    de Bruyn, G
    Whelan, TP
    Mulligan, MS
    Raghu, G
    Limaye, AP
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (08) : 1366 - 1371